Wolfe Research lowered shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Free Report) from an outperform rating to a peer perform rating in a research note released on Tuesday, Briefing.com reports.
BAYRY has been the subject of several other reports. HSBC downgraded Bayer Aktiengesellschaft from a hold rating to a reduce rating in a report on Monday, December 18th. UBS Group downgraded Bayer Aktiengesellschaft from a buy rating to a neutral rating in a report on Monday, December 4th. Deutsche Bank Aktiengesellschaft cut Bayer Aktiengesellschaft from a buy rating to a hold rating in a research report on Tuesday, November 14th. Finally, Jefferies Financial Group cut Bayer Aktiengesellschaft from a buy rating to a hold rating in a research report on Tuesday, November 21st. One research analyst has rated the stock with a sell rating and six have issued a hold rating to the company. According to MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of Hold.
Bayer Aktiengesellschaft Price Performance
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last posted its earnings results on Wednesday, November 8th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 7.98% and a positive return on equity of 15.24%. The firm had revenue of $11.26 billion during the quarter, compared to analysts’ expectations of $12.62 billion. As a group, research analysts forecast that Bayer Aktiengesellschaft will post 1.63 EPS for the current year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
- Five stocks we like better than Bayer Aktiengesellschaft
- How to Invest in Artificial Intelligence
- Does UPS stock going down present an opportunity?
- How to Invest in Apparel Stocks
- The truth behind Williams-Sonoma stock drop
- 3 Healthcare Dividend Stocks to Buy
- Is Airbnb a buy on fee increase, international growth?
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.